Analysis of the proposal for a regulation of a manufacturing exception related to the SPC and aimed to make the European industry competitive

Andriukaitis: SPC manufacturing waiver does not damage pharma innovation

Generics driving pharmerging market growth? ‘There is still opportunity for EU’ says Medicines for Europe

Up to 25,000 pharma jobs if EU alters patent rules

Access to Biosimilars in EU Expected to Continue to Outpace US and Canada

Stakeholders To Gather In London To Plan Biosimilar Market’s Future

Increasing access to cancer medicines: what role do biosimilar medicines play?

Generic industry boss: SPC manufacturing waiver won’t harm originators’ innovation

El sistema español podría mejorar su coste-eficiencia con un plan nacional

What Challenges Should Biosimilar Companies Expect In 2018?